# FDA recall D-1606-2020

> **RLC Labs Inc.** · Class II · drug recall initiated 2020-08-25.

## Product

WP Thyroid, Westhroid Pure, Thyroid USP, [liothyronine (T3) 2.25 mcg and levothyroxine (T4) 9.5 mcg], 1/4 Grain (16.25 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-5450-4; b) 60-count bottles, NDC 64727-5450-5; c) 90-count bottles, NDC 64727-5450-6; d) 100-count bottles, NDC 64727-5450-1; and e) 1,000-count bottles, NDC 64727-5450-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.

## Reason for recall

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

## Distribution

Nationwide in the United States

## Key facts

- **Recall number:** D-1606-2020
- **Recalling firm:** RLC Labs Inc.
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2020-08-25
- **Report date:** 2020-09-23
- **Termination date:** 2023-11-08

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Phoenix, AZ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1606-2020

## Citation

> AI Analytics. FDA recall D-1606-2020. Retrieved 2026-06-03 from https://api.ai-analytics.org/recall/D-1606-2020. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*